CoChat
Sign Up
Cited by 219Proteoglycans and glycosaminoglycans researchNeurogenesis and neuroplasticity mechanismsOsteoarthritis Treatment and Mechanisms

Differential regulation of expression of hyaluronan-binding proteoglycans in developing brain: aggrecan, versican, neurocan, and brevican.

Open access
Milev, Peter, Maurel, Patrice, Chiba, Atsuro, Mevissen, Markus, Popp, Susanna, Yamaguchi, Yu, Margolis, Renée K., Margolis, Richard U.·1998·Biochemical and Biophysical Research Communications
DOI 10.1006/bbrc.1998.8759
Open this paper in CoChat — free account

Abstract

We have used a slot-blot radioimmunoassay to quantitate the levels of hyaluronan-binding chondroitin sulfate proteoglycans in developing rat brain from embryonic day 14 (E 14) to eight months postnatal. Recombinant nonhomologous regions of the core proteins were used for immunization to obtain polyclonal antibodies specific for aggrecan, the alpha and beta domains of versican mRNA splice variants, and N- and C-terminal portions of neurocan, while brevican was quantitated using a specific monoclonal antibody. The concentration of aggrecan increased steadily during brain development up to 5 months of age, when it reached a level that was 18-fold higher than at E14. Alternatively spliced versican isoforms containing the alpha domain of the glycosaminoglycan attachment region were present at a relatively low level during the late embryonic and early postnatal period, decreased by approximately 50% between 1 and 2 weeks postnatal, and then increased steadily in concentration to reach a maximum at 100 days that was 7-fold that present at 10 days postnatal. In contrast to these results, versican isoforms containing the beta domain more than doubled in concentration between E14 and birth, after which they decreased by greater than 90% to reach a low "mature" level that remained unchanged between 2 and 8 months. The N- and C-terminal portions of neurocan (produced by a developmentally-regulated proteolytic cleavage in the middle of its chondroitin sulfate attachment region) both increased in embryonic brain during development, reached a peak in the early postnatal period, and then declined thereafter. As in the case of aggrecan, only traces of brevican were detected in embryonic brain and its concentration increased steadily after birth to reach an adult level that was approximately 14-fold higher than that present in neonatal brain. These striking and distinctive changes in the concentrations of the different members of this family of structurally related proteoglycans in developing brain, including changes in opposite directions for versican mRNA splice variants, indicate that the individual proteoglycans and their isoforms probably serve unique functions during nervous tissue histogenesis.

Integrity signals

Registry

Crossref · 10.1006/bbrc.1998.8759

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Neurocan expression increased between E14 and postnatal day 3 and then decreased during early-late adolescence and into adulthood.

    “Neurocan expression also increased between E14 and postnatal day (P) 3 and then decreased during early-late adolescence and into adulthood (Meyer-Puttlitz et al., 1996; Miller et al., 1996; Milev et al., 1998; Brückner et al., 2000).”

    From The Perineuronal ‘Safety’ Net? Perineuronal Net Abnormalities in Neurological Disorders (2018) · cites this paper as Milev et al., 1998

  • A developmental upregulation of aggrecan and brevican, which peak in adulthood, was reported in rat brain.

    “A developmental upregulation of aggrecan and brevican, which peak in adulthood, was reported in rat brain (Milev et al., 1998; Brückner et al., 2000; Popp et al., 2003).”

    From The Perineuronal ‘Safety’ Net? Perineuronal Net Abnormalities in Neurological Disorders (2018) · cites this paper as Milev et al., 1998

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Milev, P., Maurel, P., Chiba, A., Mevissen, M., Popp, S., Yamaguchi, Y., Margolis, R. K., & Margolis, R. U.
Affiliations
  • NYU Langone Health (US)
  • State University of New York (US)
  • Sanford Burnham Prebys Medical Discovery Institute (US)
Corresponding author
Margolis, Richard U.
ORCID
Yamaguchi, Yu
Venue
Biochemical and Biophysical Research Communications
Publisher
Elsevier BV
Published
1998-06
Volume
247
Issue
2
Pages
207-212
ISSN
0006-291X (ISSN-L)
DOI
10.1006/bbrc.1998.8759
OpenAlex
W2137502661
Cited by
219
References
20
Citations by year
2026: 4 · 2025: 4 · 2024: 7 · 2023: 6 · 2022: 3 · 2021: 6 · 2020: 11 · 2019: 8 · 2018: 9 · 2017: 6 · 2016: 6 · 2015: 8 · 2014: 10 · 2013: 8 · 2012: 10
FWCI
3.74
Type
journal article
Language
en
Open access
Licence
Locations
  • Biochemical and Biophysical Research Communications (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Proteoglycans and glycosaminoglycans research
  • Life Sciences › Neuroscience › Developmental Neuroscience › Neurogenesis and neuroplasticity mechanisms
  • Health Sciences › Medicine › Rheumatology › Osteoarthritis Treatment and Mechanisms
Keywords
chondroitin sulfate proteoglycans, brain development, aggrecan, versican, neurocan, brevican, splice variants, proteolytic cleavage, embryonic brain, postnatal brain
MeSH terms
Animals, Brain, Carrier Proteins, Hyaluronic Acid, Nerve Tissue Proteins, Chondroitin Sulfate Proteoglycans, Proteoglycans, RNA, Messenger, Extracellular Matrix Proteins, Alternative Splicing, Gene Expression Regulation, Developmental, Lectins, C-Type, Rats, Aggrecans, Versicans, Neurocan, Brevican

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review